Key result
Early aggressive immunosuppression linked to LVEF recovery to ~50% in two lupus myocarditis cases.
Why the study?
Does early aggressive immunosuppression combined with heart failure therapy improve LVEF and resolve symptoms in young women with lupus myocarditis?
Case Report (n=2)
Does early aggressive immunosuppression combined with heart failure therapy improve LVEF and resolve symptoms in young women with lupus myocarditis?
Early aggressive immunosuppression combined with guideline-directed medical therapy can lead to rapid and significant LVEF recovery in patients with acute lupus myocarditis.
No takes yet. Share an insight, caveat, or question.
May warrant cardiac evaluation in new SLE with nephritis; leaves open need for prospective validation before practice change.
Gokhale et al. (2026) conducted a case report in Systemic lupus erythematosus with lupus myocarditis and lupus nephritis (n=2). Early aggressive immunosuppression (dexamethasone, cyclophosphamide, hydroxychloroquine) and heart failure therapy was evaluated on LVEF recovery and resolution of heart failure symptoms. Early aggressive immunosuppression led to LVEF recovery from 20%-35% to 50%-55% within 1-2 months and resolution of heart failure symptoms in two women with lupus myocarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: